Arndt Vogel, MD

An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer

Background Patritumab deruxtecan (HER3-DXd) is a novel, investigational antibody-drug conjugate comprising an anti-HER3 monoclonal antibody, a tetrapeptide-based linker,...

Arndt Vogel , MD;

06/28/2021

Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial

Isocitrate dehydrogenase 1 mutation ( IDH1m ) is detected in approximately 13% of patients with cholangiocarcinoma (CCA). In the global, phase 3 ClarIDHy study evaluating ivosidenib (IVO)...

Arndt Vogel , MD;

06/25/2023

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC

Background For the therapy of previously treated BRAF V600E-mutant metastatic colorectal cancer, the combination of encorafenib with cetuximab represents a new standard ...

Arndt Vogel , MD;

06/28/2021

Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study

Fibroblast growth factor receptor 2 ( FGFR2 ) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA). Futibatinib is a highly selective, cova...

A. Hollebecque ;

Arndt Vogel , MD;

06/25/2023

Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib

Background The treatment landscape for patients with unresectable hepatocellular carcinoma (uHCC) has recently expanded. However, there is an unmet need for effective tr...

Arndt Vogel , MD;

06/28/2021

Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup

HCC is one of the most commonly diagnosed cancers globally, with an increasing number of patients affected in the ≥65 years age group. In the phase 3, open-label RATIONALE-301 trial (NCT0...

Arndt Vogel , MD;

06/25/2023

FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

Background For advanced cholangiocarcinoma, standard-of-care first-line systemic treatment is gemcitabine + cisplatin. Activating genetic alterations in patients with in...

D. Melisi ;

Eric Van Cutsem , MD, PhD;

C. Lihou ;

Arndt Vogel , MD;

06/28/2021

Cases With Panel Discussion: Management Strategy in HCC - Locoregional vs Systemic Treatment

Angela Lamarca , MD, PhD, MSc;

Lorenza Rimass , MD;

Chris J. Verslype , MD, PhD;

Jordi Rimola , MD, PhD;

Ghassan Abou-Alfa , MD, MBA;

Arndt Vogel , MD;

07/06/2023

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Background Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metas...

G. Vaccaro ;

D. Melisi ;

R. Al-Rajabi ;

A. Paulson ;

M. Borad ;

D. Gallinson ;

D. Oh ;

E. Dotan ;

Daniel Catenacci , MD;

Eric Van Cutsem , MD, PhD;

A. Murphy ;

C. Lihou ;

H. Ren ;

K. Bibeau ;

Ghassan Abou-Alfa , MD, MBA;

L. Feliz ;

V. Sahai ;

Arndt Vogel , MD;

A. Hollebecque ;

06/28/2021

Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study

Background Pembrolizumab demonstrated efficacy and a manageable adverse event profile in sorafenib-treated patients with aHCC in KEYNOTE-224, leading to accelerated approval in the Unite...

Arndt Vogel , MD;

06/27/2022